Johnson & Johnson (JNJ)

125.48
NYSE : Health Care
Prev Close 125.90
Day Low/High 125.13 / 126.36
52 Wk Low/High 107.69 / 129.00
Avg Volume 7.12M
Exchange NYSE
Shares Outstanding 2.71B
Market Cap 341.30B
EPS 6.00
P/E Ratio 21.23
Div & Yield 3.20 (2.50%)

Latest News

Why Google Has to Definitively Address Its Offensive Content Problem

Why Google Has to Definitively Address Its Offensive Content Problem

The Alphabet unit can't just 'put a band aid' on advertisers' concerns, lest it risk damaging its second-largest source of advertising revenue growth.

Can the Repeal of the Fiduciary Rule Harm Your Annuities Investments?

Can the Repeal of the Fiduciary Rule Harm Your Annuities Investments?

Annuities are in the news as Trump's appointee to head the Department of Labor spars with Sen. Warren. Here's what investors need to know.

Google's Latest Content Controversy Is Messy, but Fixable

Google's Latest Content Controversy Is Messy, but Fixable

YouTube has the resources and tools to deal with its extremist content problem. And top brands have big incentives to keep spending on the site.

Investing Your Tax Refund Now Delivers Greater Returns

Investing Your Tax Refund Now Delivers Greater Returns

While it's tempting for consumers to spend their tax refund, investing their tax dollars in an IRA or stocks now can generate a substantial amount of savings.

Johnson & Johnson Latest to Pull Ads From YouTube

Johnson & Johnson Latest to Pull Ads From YouTube

Both Verizon Communications and AT&T stated Wednesday that each would suspend digital ads on YouTube.

More Companies Pull Advertising to Protest Google's Treatment of Extremist Content

More Companies Pull Advertising to Protest Google's Treatment of Extremist Content

Britain is the second largest market for Google, generating $7.8 billion primarily from advertising in 2016.

These 3 Would Look Great at Lower Prices

These 3 Would Look Great at Lower Prices

If opportunity knocks, I'm buying.

Health Care Companies Could Be Active Today as Congress Votes

Health Care Companies Could Be Active Today as Congress Votes

The GOP is scrambling for votes on Obamacare Repeal.

Can Abbott Outperform Despite Alere?

Can Abbott Outperform Despite Alere?

Abbott Laboratories appears poised to enjoy a fruitful year, though its litigation with former takeover target Alere could hold it back.

See How Johnson & Johnson Ranks Among Analysts' Top Dow 30 Picks

See How Johnson & Johnson Ranks Among Analysts' Top Dow 30 Picks

A study of analyst recommendations at the major brokerages shows that Johnson & Johnson is the #21 broker pick, on average, out of the 30 stocks making up the Dow Jones Industrial Average, according to ETF Channel. Within the broader S&P 500, when components were ranked in terms of analyst favorites, JNJ claims the #347 spot.

Here's a Look at the 64 Best Performing Stocks Over the Last 4 Months

Here's a Look at the 64 Best Performing Stocks Over the Last 4 Months

The top 64 companies taking a trip to TheStreet's 2017 Market Bracket Challenge tournament.

Johnson & Johnson Names Winners Of First Africa Innovation Challenge

Johnson & Johnson Names Winners Of First Africa Innovation Challenge

Competition Part of Company's Eighty-Five Year Commitment to Supporting Entrepreneurs, Science Education Opportunities, and Health Systems Across the Continent

Ortho Clinical Diagnostics Announces Expansion Of Global Agreement With Astute Medical For NephroCheck Test

Ortho Clinical Diagnostics Announces Expansion Of Global Agreement With Astute Medical For NephroCheck Test

Agreement gives Ortho expanded distribution rights in Europe for the NephroCheck Test on the Astute140 platform

Who Are the Best Employers for Working Mothers?

Who Are the Best Employers for Working Mothers?

Female representation among the top 10% of earners at the NAFE top companies increased 2% to 41%, the highest since 2013.

The 10 Most Important Tips for Playing the Stock Market in March

The 10 Most Important Tips for Playing the Stock Market in March

Where should you put your money in March? TheStreet has the strategies and analysis to help guide your investment moves for the month.

Trump Tax Plan Could Make Gold Great Again

Trump Tax Plan Could Make Gold Great Again

Bigger deficits will only add to inflationary pressures, boosting precious metals.

A Lesson on the Importance of Cash

To put it simply, Stanley Black & Decker and Thermo Fisher screwed up.

Johnson & Johnson to Close UK Plant

Johnson & Johnson to Close UK Plant

The closure of the plant threatens roughly 400 jobs.

Pharma, Biotech Stocks Fall on Trump Tweets, GOP Health Care Plan

Pharma, Biotech Stocks Fall on Trump Tweets, GOP Health Care Plan

Investors are deciding what to make of an impending overhaul of the American health care system in the wake of legislative progress out of Washington.

Cramer: Top 10 Bull Markets Right Now (Part 1)

Cramer: Top 10 Bull Markets Right Now (Part 1)

Bull market number one, perhaps of all time: the financials.

Why Trump's Tax Plan Should Boost the Russell 2000

Why Trump's Tax Plan Should Boost the Russell 2000

Small-caps love lower corporate taxes and higher import duties.

Cramer: Top 10 Bull Markets Right Now

Cramer: Top 10 Bull Markets Right Now

Bull market number one, perhaps of all time: the financials.

Trump Tax Cuts Could Actually Weaken the Dollar

Trump Tax Cuts Could Actually Weaken the Dollar

Forex markets are wrong to bet on a stimulus-strengthened greenback.

How Income Investors Should Play Trump's Tax Plan

How Income Investors Should Play Trump's Tax Plan

Look for big discounts to NAV in closed-end muni bonds.

Bull Markets and Drug Rallies: Jim Cramer's Best Blog

Bull Markets and Drug Rallies: Jim Cramer's Best Blog

Jim Cramer ponders the bull market and whether the drug rally is 'Trumped up.'

Johnson & Johnson Wins Fourth Lawsuit Tied to Talcum Powder

Johnson & Johnson Wins Fourth Lawsuit Tied to Talcum Powder

Johnson & Johnson had lost its three previous cases involving the product.

Tech Stocks Under Trump

Tech Stocks Under Trump

They might have an issue with corporate tax reform.